MS drug personalised with risk diagnostic - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MS drug personalised with risk diagnostic



The FDA has approved a safety label change for Biogen and Elan’s multiple sclerosis drug Tysabri (natalizumab) after the company identified a diagnostic test that can help identify patients at risk of developing a serious brain infection, which has been associated with the drug.

The partnering of drugs and diagnostic tests is a growing trend in pharmaceutical development that has the potential to offer a more personalized approach to healthcare provisions. Such approaches can also make products more appealing to government-funded healthcare programmes by identifying patients who will or will not benefit from an expensive drug. Analysis from Bloomberg indicates that the Tysabri label change could raise sales of the drug to $1 billion in 2016.

According to a statement from Biogen and Elan, the label change will improve the risk-benefit assessment for patients with relapsing forms of multiple sclerosis. Patients using Tysabri can be at risk of the John Cunningham virus (JCV), which can cause a rare brain infection called progressive multifocal leukoencephalopathy (PML). The new label identifies JCV antibody status as a risk factor for developing PML.

The Stratify JCV Antibody ELISA test (Focus Diagnostics) can be used to qualitatively detect JCV antibodies. When used with other clinical data from the patient, the test can help healthcare providers determine the risk for developing PML. In a separate press release, the FDA has announced that it will permit marketing of the test.

George Scangos, CEO at Biogen Idec said, “Our development of the risk stratification algorithm and subsequent efforts to support the commercial availability of anti-JCV antibody testing reflect our commitment to providing patients and their physicians with additional guidance to help them make more personalized treatment decisions.”

The ability to quantify the level of JCV antibody completes a triangle of three known risk factors and should help physicians and patients better understand the balance risk-benefit balance. According to FDA, patients with the following combined three factors have the highest risk of developing PML (about 11/1000):

  • presence of anti-JCV antibodies (evidence of JCV exposure)
  • over two years of treatment with Tysabri
  • treatment with medicines known to weaken the immune system (e.g. mitoxantrone, azathioprine, methotrexate, cyclophosphamide, and mycophenolate mofetil)

The US label update follows the European Commission approval of anti-JCV antibody status as an additional factor to aid in patient risk stratification in June 2011. Globally, by the end of September 2011, there had been approximately 59,000 anti-JCV antibody tests administered commercially and through clinical trials.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here